Having trouble viewing this email? View in your browser.

26 April 2016

Dear colleagues,

An ESCMID expert contributed to the Lyme Disease Guidelines the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN) and American College of Radiology (ACR) plan to publish. You may be interested to read the panel’s response to the input received during the public comment period.

Best regards, your ESCMID communications editors


ESCMID-ASM antibiotic drug development conference 21 – 23 Sept 2016

Please save the date for the ESCMID-ASM conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will take place in Vienna, Austria, from 21 - 23 September 2016. Download the first announcement here. Registration will open in a few weeks. Antimicrobial drug resistance is an urgent problem. There are relatively few agents in developmental pipelines. Traditional pathways for drug development are expensive and slow. Both the EMA and FDA have recognized some of these obstacles for drug development. New regulation now enables accelerated drug development, with adaptive licensing until larger definitive phase III studies are completed. Such an approach enables access to drugs for patients with unmet medical needs. There is uncertainty regarding what constitutes reasonable pathways for accelerated drug development. There is a reliance on very robust preclinical studies, innovative clinical trial design, strong academic/industrial partnerships, and a requirement for early engagement with regulatory bodies. By bringing together experts from all fields (drug development, regulatory organizations, professionals) we aim to outline problems, share our current knowledge and discuss solutions. ESCMID, ASM, EMA, FDA and industry representatives have contributed to designing the program. In our opinion these two and a half days of intense discussions on the future of drug development in the antimicrobial field are a must for anyone involved in the field of antimicrobials. 

› Read more

The registration deadline for the Staphylococcus course in Lyon is 20 May

The postgraduate education course Virulence and Resistance in Staphylococcus aureus: 2016 State of the Art will take place in Lyon, France, from 28 June – 1 July 2016. The objective is to provide postgraduate microbiologists and infectious disease physicians with an updated overview of pathophysiology and resistance in Staphylococcus. Participants are given the opportunity to have state-of-the-art insights and scientific exchanges on virulence and resistance on these pathogens. The presentations include topics such as mechanisms of resistance and virulence in vivo data, clinical management, screening, detection and identification of virulence and resistance determinants in the daily laboratory as well as infection control practice.

› Read more

Application for observerships with ECDC in Stockholm opens 2 May

ESCMID members with a focus on public health may apply for an observership with the European Centre for Disease Prevention and Control in Stockholm. A group of 10 observers are offered a five-day programme at the ECDC from 5 – 9 September 2016.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.